Abstract
Orphan drug status offer incentives for drug development, registration and market exclusivity. The objective of this study is to determine if orphan status confers any pricing incentives in the U4 markets + the United-Kingdom (UK) and to compare the level of incentives between these countries.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
